The preliminary results of another ongoing phase II trial of pembrolizumab showed that of nine women with MMR-deficient, persistent, or recurrent endometrial cancer, 56% had an ORR (n 1⁄4 5), including one complete response and four partial responses. This evidence concerns the gene MRC1 and endometrial cancer.